ArticleThorax2024
Availability, cost and affordability of essential medicines for chronic respiratory diseases in low-income and middle-income countries: a cross-sectional study.
Article in Thorax, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Cost-effectiveness of anti-inflammatory reliever (AIR) or maintenance and reliever therapy (MART) for mild to moderate asthma: a systematic review.BMJ open respiratory research · 2026Article
- Article
- Revealing inequities in chronic respiratory disease (CRD) care: An adapted Photovoice qualitative study in Malaysian primary care settings.NPJ primary care respiratory medicine · 2026Article
- Usability of the test of adherence to inhalers toolkit to patients with COPD in Kyrgyzstan.NPJ primary care respiratory medicine · 2026Observational
- Amplifying the voices of people with chronic respiratory diseases (CRDs) care through photovoice: a case study of patient and public involvement in Klang, Malaysia.Research involvement and engagement · 2026Article
- Addressing the Global Challenges of COPD and Asthma: A Shared Vision From the Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) and the Global Initiative for Asthma (GINA).Respirology (Carlton, Vic.) · 2026Article
- South African Thoracic Society position statement on asthma in children, adolescents and adults.African journal of thoracic and critical care medicine · 2026Article
- The forgotten billion: bridging the global allergy care chasm through scalable, equity-driven strategies.Frontiers in allergy · 2026Review
- Exploring factors affecting access to non-communicable disease medicines in low- and middle-income countries: a systematic review.BMJ public health · 2026Article
- Article
- Article
- Article
- Effectiveness of inhaled therapies in asthma among adults in Northern Sri Lanka, a low-income and middle-income country: a prospective observational study.BMJ open respiratory research · 2025Observational
- Beliefs surrounding the use of inhaled asthma medication in The Gambia: a qualitative study of asthma patients and healthcare workers.NPJ primary care respiratory medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Contemporary data on the availability, cost and affordability of essential medicines for chronic respiratory diseases (CRDs) across low-income and middle-income countries (LMICs) are missing, despite most people with CRDs living in LMICs. Cross-sectional data for seven CRD medicines in pharmacies, healthcare facilities and central medicine stores were collected from 60 LMICs in 2022-2023. Medicines for symptomatic relief were widely available and affordable, while preventative treatments varied widely in cost, were less available and largely unaffordable. There is an urgent need to address these issues if the Sustainable Development Goal 3 is to be achieved for people with asthma by 2030.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.